Camblong Jurgi 4
4 · SOPHiA GENETICS SA · Filed Jul 1, 2026
Research Summary
AI-generated summary of this filing
SOPHiA GENETICS (SOPH) Exec Chairman Camblong Exercises Options, Sells Shares
What Happened
- Jurgi Camblong, Executive Chairman and Director of SOPHiA GENETICS (SOPH), exercised stock options and sold the resulting shares. On 2026-06-29 and 2026-06-30 he exercised a total of 63,479 option shares at $3.16 per share (total cost $200,594) and sold a total of 83,679 shares in open-market transactions for aggregate gross proceeds of about $506,690.
- The sales were larger in volume than the exercises (shares sold exceed shares exercised because multiple prior holdings were also disposed). The exercises indicate option conversion; the subsequent sales were executed under a Rule 10b5-1 trading plan (see Key Details).
Key Details
- Transaction dates: 2026-06-29 and 2026-06-30.
- Exercises (code M): 18,060 shares on 6/29 and 45,419 shares on 6/30 at $3.16 each (total paid $200,594).
- Sales (code S): 18,060 @ $5.87 (6/29), 350 @ $6.00 (6/29), 45,419 @ $6.14 (6/30), 19,650 @ $6.02 (6/30), 200 @ $6.30 (6/30). Total cash proceeds ≈ $506,690.
- Some Form 4 lines show $0 dispositions for 18,060 and 45,419 shares — these reflect conversion of derivative option holdings into common shares (bookkeeping), not additional cash sales.
- Sales price details: weighted-average prices reported; ranges disclosed in footnotes — 6.10–6.30 and 6.00–6.03 for portions of the sales. The filer can provide per-trade prices on request.
- Options status: options were fully vested (footnote) and, after these transactions, the reporting person held an aggregate of 4,646,057 derivative stock options across remaining tranches (prior line showed 4,691,476 before the later exercise).
- Sales were made pursuant to a pre-established Rule 10b5-1 trading plan (footnote F1).
- Filing date was 2026-07-01 for transactions on 6/29–6/30; appears to have been filed within standard Form 4 timing requirements.
Context
- This is an option exercise followed by open-market sales (i.e., the insider exercised options and sold shares) — a common way for insiders to monetize vested options. Because the sales were made under a 10b5-1 plan, they are typically pre-arranged and not necessarily a contemporaneous signal of the insider’s view.
- For retail investors: purchases are generally more informative about insider bullishness; here the net activity was a conversion of options and sale of shares, not a fresh cash purchase of stock.
- All statements above are factual descriptions of the Form 4 entries; no inference is made about the insider’s motives.
Insider Transaction Report
Form 4
Camblong Jurgi
DirectorExecutive Chairman
Transactions
- Exercise/Conversion
Ordinary Shares
[F1]2026-06-29$3.16/sh+18,060$57,070→ 3,619,553 total - Sale
Ordinary Shares
[F1]2026-06-29$5.87/sh−18,060$105,958→ 3,601,493 total - Sale
Ordinary Shares
[F1]2026-06-29$6.00/sh−350$2,100→ 3,601,143 total - Exercise/Conversion
Ordinary Shares
[F1]2026-06-30$3.16/sh+45,419$143,524→ 3,646,562 total - Sale
Ordinary Shares
[F1][F2]2026-06-30$6.14/sh−45,419$279,050→ 3,601,143 total - Sale
Ordinary Shares
[F1][F3]2026-06-30$6.02/sh−19,650$118,322→ 3,581,493 total - Sale
Ordinary Shares
[F1]2026-06-30$6.30/sh−200$1,260→ 3,581,293 total - Exercise/Conversion
Share Option (Right to Buy)
[F1][F4][F5]2026-06-29−18,060→ 50,000 totalExercise: $3.16Exp: 2028-11-29→ Ordinary Shares (18,060 underlying) - Exercise/Conversion
Share Option (Right to Buy)
[F1][F4][F6]2026-06-30−45,419→ 4,581 totalExercise: $3.16Exp: 2028-11-29→ Ordinary Shares (45,419 underlying)
Footnotes (6)
- [F1]Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.10 to $6.30, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.03, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The share options are fully vested and exercisable.
- [F5]Following the transaction reported on this line, the Reporting Person holds an aggregate total of 4,691,476 derivative stock options across all remaining grant tranches with varying exercise prices.
- [F6]Following the transaction reported on this line, the Reporting Person holds an aggregate total of 4,646,057 derivative stock options across all remaining grant tranches with varying exercise prices.
Signature
/s/ Elimara Brunetto as Attorney-in- Fact for Jurgi Camblong|2026-07-01